EUVIMEDEUVIMED entdecken
Crossref

Timing of Radiographic Progression Relative to Prostate-Specific Antigen Kinetics in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving Upfront Androgen Receptor Signaling Inhibitor Therapy.

Akinori Nakayama, Erika Ikezoe, Minoru Inoue, Hiroki Tsujioka, Asumi Nirazuka, Keita Izumi, Kiyoshi Setoguchi, Kazutaka Saito

Urology journal./Urology jornal. · 20.09.2026 · 23 (4) · 167-171

DOI: 10.22037/uj.v23i04.8771 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Urology journal./Urology jornal., erschienen am 20.09.2026. Verfasst von Akinori Nakayama und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama 343- 8555, Japan. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Prostate-specific antigen (PSA) progression does not always coincide with radiographic progression in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving upfront androgen receptor signaling inhibitor (ARSI) therapy. We evaluated the timing of radiographic progression according to predefined PSA kinetic periods. MATERIALS AND METHODS: We retrospectively reviewed 82 consecutive patients with synchronous mCSPC treated with upfront ARSI therapy between April 2018 and May 2024. The median follow-up duration was 23 months (interquartile range [IQR], 14-38). PSA kinetics were categorized into three predefined periods: pre-PSA nadir (treatment initiation to PSA nadir), post-PSA nadir/before PSA progression (PSA nadir to PSA progression), and post-PSA progression. Radiographic progression events were classified according to these PSA kinetic periods. RESULTS: During follow-up, 33 patients (40%) experienced PSA progression and 26 (31.7%) developed radiographic progression. Among the 26 radiographic progression events, 1 (3.8%) occurred during the pre-PSA nadir period, 7 (26.9%) during the post-PSA nadir/before PSA progression period, and 18 (69.2%) during the post- PSA progression period. Overall, 25 of 26 radiographic progression events (96.2%; 95% confidence interval [CI]: 81.1%-99.3%) occurred after PSA nadir. The only patient who developed radiographic progression before PSA nadir was subsequently diagnosed with small-cell carcinoma of the prostate. PSA nadir levels and time to PSA nadir were comparable between patients who developed radiographic progression before and after PSA progression. CONCLUSION: Radiographic progression before PSA nadir was uncommon in this cohort, whereas a substantial proportion of progression events occurred after PSA nadir but before PSA progression. These findings suggest that PSA nadir may serve as a useful temporal reference point for radiographic surveillance during upfront ARSI therapy. However, these observations should be considered hypothesis-generating and require validation in larger prospective multicenter studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsHumansMaleDisease ProgressionRetrospective StudiesTime FactorsAgedMiddle AgedRadiography

Substanzen

Prostate-Specific AntigenAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Department of Urology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama 343- 8555, Japan.

Zitieren

APA

Nakayama, A., Ikezoe, E., Inoue, M., Tsujioka, H., Nirazuka, A., Izumi, K., Setoguchi, K., & Saito, K. (2026). Timing of Radiographic Progression Relative to Prostate-Specific Antigen Kinetics in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving Upfront Androgen Receptor Signaling Inhibitor Therapy. Urology journal./Urology jornal., 23(4), 167-171. https://doi.org/10.22037/uj.v23i04.8771

Vancouver

Nakayama A, Ikezoe E, Inoue M, Tsujioka H, Nirazuka A, Izumi K, et al. Timing of Radiographic Progression Relative to Prostate-Specific Antigen Kinetics in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving Upfront Androgen Receptor Signaling Inhibitor Therapy. Urology journal./Urology jornal.. 2026;23(4):167-171. doi:10.22037/uj.v23i04.8771

BibTeX
@article{Nakayama2026,
  author = {Nakayama, Akinori and Ikezoe, Erika and Inoue, Minoru and Tsujioka, Hiroki and Nirazuka, Asumi and Izumi, Keita and Setoguchi, Kiyoshi and Saito, Kazutaka},
  title = {Timing of Radiographic Progression Relative to Prostate-Specific Antigen Kinetics in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving Upfront Androgen Receptor Signaling Inhibitor Therapy},
  journal = {Urology journal./Urology jornal.},
  year = {2026},
  volume = {23},
  number = {4},
  pages = {167--171},
  doi = {10.22037/uj.v23i04.8771}
}
Kostenlos starten →